Beach Investment Counsel Inc. PA lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 285,938 shares of the company’s stock after selling 710 shares during the period. Johnson & Johnson accounts for about 3.9% of Beach Investment Counsel Inc. PA’s investment portfolio, making the stock its 6th largest position. Beach Investment Counsel Inc. PA’s holdings in Johnson & Johnson were worth $37,175,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors also recently added to or reduced their stakes in the company. Mosaic Family Wealth LLC grew its holdings in shares of Johnson & Johnson by 10.4% in the third quarter. Mosaic Family Wealth LLC now owns 12,351 shares of the company’s stock valued at $1,606,000 after purchasing an additional 1,159 shares in the last quarter. Intact Investment Management Inc. boosted its stake in Johnson & Johnson by 0.9% during the third quarter. Intact Investment Management Inc. now owns 67,400 shares of the company’s stock worth $8,761,000 after buying an additional 600 shares during the period. Traynor Capital Management Inc. boosted its stake in Johnson & Johnson by 3.5% during the third quarter. Traynor Capital Management Inc. now owns 10,822 shares of the company’s stock worth $1,401,000 after buying an additional 368 shares during the period. Crossmark Global Holdings Inc. purchased a new position in Johnson & Johnson during the third quarter worth $10,634,000. Finally, SPC Financial Inc. boosted its stake in Johnson & Johnson by 208.8% during the third quarter. SPC Financial Inc. now owns 11,611 shares of the company’s stock worth $1,510,000 after buying an additional 7,851 shares during the period. Hedge funds and other institutional investors own 65.79% of the company’s stock.
Several research analysts have commented on the stock. Stifel Nicolaus lifted their price objective on shares of Johnson & Johnson from $142.00 to $145.00 and gave the stock a “hold” rating in a research note on Wednesday, January 24th. BTIG Research reaffirmed a “sell” rating and set a $110.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, January 24th. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 price objective for the company in a research note on Tuesday, January 23rd. Credit Suisse Group set a $154.00 target price on shares of Johnson & Johnson and gave the company a “hold” rating in a research note on Monday, January 22nd. Finally, Wells Fargo & Co reissued an “outperform” rating and set a $160.00 target price (up from $155.00) on shares of Johnson & Johnson in a research note on Friday, January 12th. Four research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the company. Johnson & Johnson presently has a consensus rating of “Hold” and a consensus target price of $146.16.
Johnson & Johnson (JNJ) traded down $2.34 during mid-day trading on Friday, hitting $137.68. The company had a trading volume of 9,197,500 shares, compared to its average volume of 7,360,000. The company has a market capitalization of $369,880.00, a P/E ratio of 353.03, a P/E/G ratio of 2.47 and a beta of 0.74. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. Johnson & Johnson has a 12-month low of $112.62 and a 12-month high of $148.32.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, January 23rd. The company reported $1.74 EPS for the quarter, topping the Zacks’ consensus estimate of $1.72 by $0.02. The business had revenue of $20.20 billion during the quarter, compared to the consensus estimate of $20.08 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 27.80%. The firm’s revenue was up 11.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.58 earnings per share. analysts predict that Johnson & Johnson will post 8.11 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a yield of 2.44%. Johnson & Johnson’s dividend payout ratio is presently 861.54%.
TRADEMARK VIOLATION WARNING: “Johnson & Johnson (JNJ) is Beach Investment Counsel Inc. PA’s 6th Largest Position” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/02/04/beach-investment-counsel-inc-pa-cuts-position-in-johnson-johnson-jnj.html.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.